|
PI3K/AKT-IN-1
|
P659144-25mg
|
≥99% |
N/A |
25mg
|
¥ 9200.9
|
期货,请咨询 |
|
0 |
阿拉丁 |
|
PI3K/AKT-IN-1
|
P659144-10mg
|
≥99% |
N/A |
10mg
|
¥ 4200.9
|
期货,请咨询 |
|
0 |
阿拉丁 |
|
Poly (I:C):Kanamycin (1:1)
|
P659139-50mg
|
|
N/A |
50mg
|
¥ 3600.9
|
期货,请咨询 |
|
0 |
阿拉丁 |
|
Poly (I:C):Kanamycin (1:1)
|
P659139-25mg
|
|
N/A |
25mg
|
¥ 2100.9
|
期货,请咨询 |
|
0 |
阿拉丁 |
|
Poly (I:C):Kanamycin (1:1)
|
P659139-10mg
|
|
N/A |
10mg
|
¥ 900.9
|
期货,请咨询 |
|
0 |
阿拉丁 |
|
Poly (I:C):Kanamycin (1:1)
|
P659139-100mg
|
|
N/A |
100mg
|
¥ 5700.9
|
期货,请咨询 |
|
0 |
阿拉丁 |
|
PARP10/15-IN-1
|
P659130-5mg
|
≥95% |
N/A |
5mg
|
¥ 1800.9
|
期货,请咨询 |
|
0 |
阿拉丁 |
|
PARP10/15-IN-1
|
P659130-50mg
|
≥95% |
N/A |
50mg
|
¥ 9900.9
|
期货,请咨询 |
|
0 |
阿拉丁 |
|
PARP10/15-IN-1
|
P659130-25mg
|
≥95% |
N/A |
25mg
|
¥ 6300.9
|
期货,请咨询 |
|
0 |
阿拉丁 |
|
PARP10/15-IN-1
|
P659130-10mg
|
≥95% |
N/A |
10mg
|
¥ 3150.9
|
期货,请咨询 |
|
0 |
阿拉丁 |
|
PARP10/15-IN-1
|
P659130-100mg
|
≥95% |
N/A |
100mg
|
¥ 14850.9
|
期货,请咨询 |
|
0 |
阿拉丁 |
|
PEG2000-DSPE
|
P659113-5mg
|
≥98% |
N/A |
5mg
|
¥ 500.9
|
期货,请咨询 |
|
0 |
阿拉丁 |
|
PEG2000-DSPE
|
P659113-50mg
|
≥98% |
N/A |
50mg
|
¥ 2600.9
|
期货,请咨询 |
|
0 |
阿拉丁 |
|
PEG2000-DSPE
|
P659113-25mg
|
≥98% |
N/A |
25mg
|
¥ 1600.9
|
期货,请咨询 |
|
0 |
阿拉丁 |
|
PEG2000-DSPE
|
P659113-10mg
|
≥98% |
N/A |
10mg
|
¥ 800.9
|
期货,请咨询 |
|
0 |
阿拉丁 |
|
PEG2000-DSPE
|
P659113-100mg
|
≥98% |
N/A |
100mg
|
¥ 4100.9
|
期货,请咨询 |
|
0 |
阿拉丁 |
|
PD-1/PD-L1-IN 3 TFA
|
P659098-5mg
|
≥99% |
N/A |
5mg
|
¥ 4500.9
|
期货,请咨询 |
|
0 |
阿拉丁 |
|
PD-1/PD-L1-IN 3 TFA
|
P659098-1mg
|
≥99% |
N/A |
1mg
|
¥ 1500.9
|
期货,请咨询 |
|
0 |
阿拉丁 |
|
PD-1/PD-L1-IN 3 TFA
|
P659098-10mg
|
≥99% |
N/A |
10mg
|
¥ 6800.9
|
期货,请咨询 |
|
0 |
阿拉丁 |
|
P2X7-IN-2 TFA
|
P659097-5mg
|
≥99% |
N/A |
5mg
|
¥ 8100.9
|
期货,请咨询 |
|
0 |
阿拉丁 |
|
P2X7-IN-2 TFA
|
P659097-10mg
|
≥99% |
N/A |
10mg
|
¥ 13000.9
|
期货,请咨询 |
|
0 |
阿拉丁 |
|
PD-L1-IN-1
|
P659082-5mg
|
≥99% |
N/A |
5mg
|
¥ 1599.9
|
现货 |
|
0 |
阿拉丁 |
|
PD-L1-IN-1
|
P659082-50mg
|
≥99% |
N/A |
50mg
|
¥ 6999.9
|
现货 |
|
0 |
阿拉丁 |
|
PD-L1-IN-1
|
P659082-25mg
|
≥99% |
N/A |
25mg
|
¥ 4999.9
|
现货 |
|
0 |
阿拉丁 |